Summary:
Retinoic acid receptors (RARs), such as RARG, are nuclear hormone receptors that act as ligand-dependent transcriptional regulators. In their liganded state, RARs activate transcription, whereas in their nonliganded form, they repress transcription of their target genes. RARs have numerous target genes, which have retinoic response elements in their promoter regions (summary by Walkley et al., 2007 [PubMed 17574023]).[supplied by OMIM] (PubMed Links)
|
| Domains and Motifs:
HOLI: Ligand binding domain of hormone receptors ZnF_C4: c4 zinc finger in nuclear hormone receptors
|
Gene Ontology:
KEGG - Enzyme ID(s): KEGG - Orthology:
K08529
|
KEGG - Pathway(s):
None Available
|
Nomenclature / Alternative Names:
RAR gamma 1; RARC; NR1B3; Retinoic acid receptor gamma isoform 1; Retinoic acid receptor gamma isoform 2
|
Approved Symbol:
| (De-) Phosphorylations:
Phosphorylation Targets:
Total phosphorylation targets: 0 |
Human phosphorylation targets: 0; | Predicted platelet targets: 0 |
| Protein Characteristics:
| Associated Drugs (DrugBank Accession):
3-FLUORO-4-[2-HYDROXY-2-(5,5,8,8-TETRAMETHYL-5,6,7,8,-TETRAHYDRO-NAPHTALEN-2-YL)-ACETYLAMINO]-BENZOIC ACID(db); 4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid(db); Acitretin(db); Adapalene(db); Alitretinoin(db); BMS184394(db); CD564(db); Dodecyl-Alpha-D-Maltoside(db); Etretinate(db); R-3-FLUORO-4-[2-HYDROXY-2-(5,5,8,8-TETRAMETHYL-5,6,7,8,-TETRAHYDRO-NAPHTALEN-2-YL)-ACETYLAMINO]-BENZOIC ACID(db); SR11254(db); Tazarotene(db); Tretinoin(db)
Associated Genetic Diseases:
None Available
| Predicted Transmembrane Domains:
Isoform 2 : 0 Isoform 1 : 0
|
| |
|